Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06780449 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06780449: Active Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
NCT06780449 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 400 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06780449, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.
Primary Outcome
Measured in percentage (%).
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Cagrilintide
- DRUG Placebo cagrilintide
- DRUG Placebo semaglutide
Study Locations (20)
Other
- Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie - Brussels
- UZA - UZ Antwerpen - Department of Endocrinology - Edegem
- UZ Leuven - Endocrinology - Leuven
- CHU Helora - Hôpital de Mons - Site Constantinople - Mons
- Alpha Recherche Clinique - Lebourgneuf - Québec
- Aarhus Universitetshospital, Steno Diabetes Center Aarhus - Aarhus
- Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden - Esbjerg
California
- Valley Clinical Trials - Covina
- Diablo Clinical Research, Inc. - Walnut Creek
Connecticut
- Yale University School Of Medicine - New Haven
Hawaii
- East West Medical Research Institute_Honolulu - Honolulu
Kentucky
- L-MARC Research Center - Louisville
Missouri
- StudyMetrix Research LLC - City of Saint Peters
South Carolina
- Spartanburg Medical Research - Spartanburg
Tennessee
- Holston Medical Group_Bristol - Bristol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 3 |
What the registry record for NCT06780449 still lists
NCT06780449 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.
NCT06780449 names 20 study sites across 13 states, led by Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06780449 about?
NCT06780449 is a clinical study titled "A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity". This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 year...
What is the current status of trial NCT06780449?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-02-10. Estimated completion is 2028-10-31.
What conditions does trial NCT06780449 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06780449?
The interventions under investigation include: Semaglutide (DRUG), Cagrilintide (DRUG), Placebo cagrilintide (DRUG), Placebo semaglutide (DRUG).
Who is sponsoring clinical trial NCT06780449?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06780449 being conducted?
This trial has 20 study locations across California, Connecticut, Hawaii, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06780449's enrollment target sits among peer trials
400 170th of 1053 higher than 881 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI